Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $185.61M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 1.58M
Average 0.22M
PRE Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Prenetics Global LimitedNASDAQ: PRE
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue falls 52.4% from a year ago
Deferred revenue stood at $2.95M at the end of Q1 FY2026, down 52.4% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -18.4% a year.
Context
- Deferred revenue amounted to 1.7% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
- Deferred revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -52.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 3.09M USD
- Year-over-year change
- -52.5%
- 4-year CAGR
- -24.7%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.09M | -52.5% |
| FY2024 | 2024-12-31 | 6.49M | +6.2% |
| FY2023 | 2023-12-31 | 6.11M | +7.7% |
| FY2022 | 2022-12-31 | 5.67M | -40.8% |
| FY2021 | 2021-12-31 | 9.59M | — |
Deferred Revenue vs competitors
How PRE compares with its peers on the latest reported figures
- PRE's Mar 2026 deferred revenue of $2.95M is the 2nd highest of the 11 companies compared; the peer median is $433.76K.
- Its year-over-year change of -52.4% is the 5th highest of 7, against a peer median of -23.9%.
- Deferred revenue amounts to 1.7% of total assets for PRE, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.27M | -21.1% | — | 1.7% | |
| Mar 2026 | $2.95M | -52.4% | -18.4% | 1.7% | |
| Mar 2026 | $872K | -65.3% | -12.6% | 0.2% | |
| Mar 2026 | $866K | +97.7% | -20.1% | 0.7% | |
| Mar 2026 | $833K | +6.1% | -27.5% | 0.7% | |
| Mar 2026 | $465.53K | -26.8% | — | 0.6% | |
| Mar 2026 | $402K | -94.7% | -74.1% | 0.7% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $0 | — | — | 0.0% |
ATLNAtlantic International Corp. | Dec 2025 | $0 | — | — | 0.0% |
| Peer median (excluding PRE) | $433.76K | -23.9% | -23.8% | 0.4% | |
Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.29M | 146.66M | 45.71M | 52.25M | 32.13M |
| Short-term Investments | 9.91M | 37.46M | 27.03M | 10.56M | 29.36M |
| Net Receivables | 47.05M | 42.5M | 5.29M | 5.61M | 2.98M |
| Inventory | 6.83M | 4.53M | 3.13M | 6.57M | 7.06M |
| Other Current Assets | 7.31M | 4.58M | 8.31M | 3.55M | 11.86M |
| Total Current Assets | 106.89M | 241.81M | 93.66M | 86.15M | 83.39M |
| Property, Plant & Equipment (Net) | 13.04M | 13.1M | 5.78M | 7.81M | 1.76M |
| Goodwill | 3.98M | 33.8M | 29.17M | 37.36M | 0 |
| Intangible Assets | 23.83M | 14.79M | 13.43M | 11.57M | 44.7M |
| Long-term Investments | 0 | 788.47K | 107.84M | 69.33M | 67M |
| Tax Assets | 79.7K | 243.45K | 28K | 0 | 0 |
| Other Non-current Assets | 693.55K | 7.6M | 4.27M | 1.35M | 6.68M |
| Total Non-current Assets | 41.61M | 70.32M | 160.51M | 127.43M | 120.13M |
| Total Assets | 148.51M | 312.13M | 254.17M | 213.58M | 203.52M |
| Account Payables | 9.98M | 7.29M | 1.67M | 3.67M | 7.73M |
| Short-term Debt | 1.67M | 0 | 0 | 0 | 1.33M |
| Tax Payables | 1.22M | 8.65M | 7.44M | 78K | 0 |
| Deferred Revenue | 9.59M | 5.67M | 6.11M | 6.49M | 3.09M |
| Other Current Liabilities | 22.64M | 17.47M | 15.49M | 15.07M | 15.5M |
| Total Current Liabilities | 58.74M | 57.2M | 39.48M | 36.55M | 27.67M |
| Long-term Debt | 486.4M | 0 | 0 | 0 | 437K |
| Deferred Tax Liabilities | 659.5K | 3.19M | 2.62M | 2.17M | 8K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 4.52M | 1.05M | 499K | 460K |
| Total Non-current Liabilities | 490.66M | 11.47M | 4.53M | 5.68M | 1.34M |
| Total Liabilities | 549.4M | 68.67M | 44.01M | 42.23M | 29.01M |
| Common Stock | 1.49K | 13.7K | 18K | 19K | 25K |
| Retained Earnings | 0 | (408.04M) | (470.77M) | (517.07M) | 0 |
| Accumulated OCI | (400.81M) | (185.69M) | (176.03M) | (169.25M) | 0 |
| Other Stockholders Equity | (24K) | 0 | 0 | 0 | 174.58M |
| Minority Interest | (84.98K) | 6.4M | 3.8M | 957K | (93K) |
| Total Equity | (400.89M) | 243.46M | 210.16M | 171.35M | 174.51M |
| Total Debt | 491.67M | 6.65M | 2.37M | 5.77M | 2.2M |
| Net Debt | 456.38M | (140.01M) | (43.34M) | (46.48M) | (29.93M) |
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.